{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:23:44Z","timestamp":1790245424676,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.leukres.2018.06.014","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T05:15:03Z","timestamp":1530335703000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms"],"prefix":"10.1016","volume":"71","author":[{"given":"J.","family":"Berdeja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Walgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.06.014_bib0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.hoc.2014.08.003","article-title":"Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease","volume":"28","author":"Salit","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2018.06.014_bib0010","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.14694\/EdBook_AM.2015.35.e389","article-title":"Current therapies and their indications for the philadelphia-negative myeloproliferative neoplasms","volume":"35","author":"Kiladjian","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.leukres.2018.06.014_bib0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.leukres.2018.06.014_bib0020","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0025","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.06.014_bib0030","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1182\/blood-2007-05-090308","article-title":"Identification of somatic JAK1 mutations in patients with acute myeloid leukemia","volume":"111","author":"Xiang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0035","first-page":"114","article-title":"JAK2 negative polycythemia vera","volume":"2","author":"Geetha","year":"2010","journal-title":"J. Lab. Phys."},{"key":"10.1016\/j.leukres.2018.06.014_bib0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2Exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.leukres.2018.06.014_bib0045","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.13223","article-title":"Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.06.014_bib0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2018.06.014_bib0055","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood-2016-01-694182","article-title":"Mutant calreticulin: when a chaperone becomes intrusive","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.leukres.2018.06.014_bib0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.leukres.2018.06.014_bib0070","unstructured":"Data on file [Lilly]."},{"key":"10.1016\/j.leukres.2018.06.014_bib0075","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/bcj.2013.6","article-title":"Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F","volume":"3","author":"Ma","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2018.06.014_bib0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood.V122.21.665.665","article-title":"Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)","volume":"122","author":"Verstovsek","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0085","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0090","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0095","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1017\/S1355617710000330","article-title":"Complex activities of daily living vary by mild cognitive impairment subtype","volume":"16","author":"Bangen","year":"2010","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.leukres.2018.06.014_bib0110","first-page":"155","article-title":"EuroQol-5D (EQ-5D): an instrument for measuring quality of life","volume":"78","author":"Balestroni","year":"2012","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.leukres.2018.06.014_bib0115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2018.06.014_bib0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V114.22.753.753","article-title":"An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients","volume":"114","author":"Moliterno","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2013-0198","article-title":"AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors","volume":"18","author":"Plimack","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2018.06.014_bib0130","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5","article-title":"Results of the Persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts <100,000\/\u03bcl","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.06.014_bib0135","unstructured":"Press Releases [Internet]. Gilead. [cited 2017Jul]. Available from: http:\/\/www.gilead.com\/news\/press-releases\/2016\/11\/gilead-announces-topline-results-from-two-phase-3-studies-evaluating-momelotinib-for-patients-with-myelofibrosis."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:16Z","timestamp":1758934756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":27,"alternative-id":["S0145212618301371"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.06.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}